Trials / Completed
CompletedNCT05397600
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 684 (actual)
- Sponsor
- Laboratoires Thea · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost Ophthalmic | Eyedrops |
Timeline
- Start date
- 2022-06-22
- Primary completion
- 2024-03-07
- Completion
- 2024-03-07
- First posted
- 2022-05-31
- Last updated
- 2024-07-18
Locations
64 sites across 3 countries: United States, Canada, Colombia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05397600. Inclusion in this directory is not an endorsement.